Potential contraindications for solid organ transplant are subject to the judgment of the transplant center and may include but is not limited to the following:
- Known current malignancy, including metastatic cancer; or
- Recent malignancy with high risk of recurrence; or
- Untreated systemic infection making immunosuppression unsafe, including chronic infection; or
- Other irreversible end-stage diseases not attributed to liver disease; or
- History of cancer with a moderate risk of recurrence; or
- Systemic disease that could be exacerbated by immunosuppression; or
- Psychosocial conditions or chemical dependency affecting ability to adhere to therapy.
The MELD and PELD scores range from six (6) (less ill) to 40 (gravely ill). The MELD and PELD scores will change during an individual's tenure on the waiting list.
Individuals with liver disease related to alcohol or drug abuse must be actively involved in a substance abuse treatment program.
Tobacco consumption is a contraindication.
Individuals with polycystic disease of the liver do not develop liver failure but may require transplantation
due to the anatomic complications of a hugely enlarged liver. The MELD and PELD score may not apply to these cases. One of the following complications should be present:
- Enlargement of liver impinging on respiratory function; or
- Extremely painful enlargement of liver; or
- Enlargement of liver significantly compressing and interfering with function of other abdominal organs.
Individuals with familial amyloid polyneuropathy do not experience liver disease per se, but develop polyneuropathy and cardiac amyloidosis due to the production of a variant transthyretin molecule by the liver. MELD and PELD exception criteria and scores may apply to these cases. Candidacy for liver transplant is an individual consideration based on the morbidity of the polyneuropathy. Many individuals may not be candidates for liver transplant alone due to coexisting cardiac disease; or (Go back Over)
Criteria used for individual selection of hepatocellular carcinoma (HCC) individuals eligible for liver transplant include the Milan criteria,which is considered the criterion standard,the University of California, San Francisco expanded criteria,and United Network of Organ Sharing (UNOS) criteria.
A single tumor 5 cm or less or 2 to 3 tumors 3 cm or less.
University of California, San Francisco Expanded Criteria
A single tumor 6.5 cm or less or up to 3 tumors 4.5 cm or less, and a total tumor size of 8 cm or less.
UNOS Stage T2 Criteria
A single tumor 2 cm or greater and up to 5 cm or less or 2 to 3 tumors 1 cm or greater and up to 3 cm or less and without extrahepatic spread or macrovascular invasion.
Individuals with HCC are appropriate candidates for liver transplant only if the disease remains confined to the liver. Therefore, the individual should be periodically monitored while on the waiting list, and if metastatic disease develops, the individual should be removed from the transplant waiting list. Also, at the time of transplant, a backup candidate should be scheduled. If locally extensive or metastatic cancer is discovered at the time of exploration before hepatectomy, the transplant should be aborted, and the backup candidate scheduled for transplant.
Note that liver transplant for those with T3 HCC is not prohibited by UNOS guidelines, but such individuals do not receive any priority on the waiting list. All individuals with HCC awaiting transplant are reassessed at 3-month intervals. Those whose tumors have progressed and are no longer stage T2 will lose the additional allocation points.
Additionally, nodules identified through imaging of cirrhotic livers are given a class 5 designation. Class 5B and 5T nodules are eligible for automatic priority. Class 5B criteria consist of a single nodule 2 cm or larger and up to 5 cm (T2 stage) that meets specified imaging criteria. Class 5T nodules have undergone subsequent locoregional treatment after being automatically approved on initial application or extension. A single class 5A nodule (greater than 1 cm and less than 2 cm) corresponds to T1 HCC and does not qualify for automatic priority. However, combinations of class 5A nodules are eligible for automatic priority if they meet stage T2 criteria. Class 5X lesions are outside of stage T2 and ineligible for automatic exception points. Nodules less than 1 cm are considered indeterminate and are not considered for additional priority. Therefore, the UNOS allocation system. provides strong incentives to use locoregional therapies to downsize tumors to T2 status and to prevent progression while on the waiting list.
According to the Organ Procurement and Transplant Network policy on liver allocation, candidates with cholangiocarcinoma meeting the following criteria will be eligible for a MELD or PELD exception with a 10% mortality equivalent increase every three (3) months:
- Centers must submit a written protocol for individual care to the OPTN and UNOS Liver and Intestinal Organ Transplant Committee before requesting a MELD score exception for a candidate with cholangiocarcinoma. This protocol should include selection criteria, administration of neoadjuvant therapy before transplant, and operative staging to exclude individuals with regional hepatic lymph node metastases, intrahepatic metastases, and/or extrahepatic disease. The protocol should include data collection as deemed necessary by the OPTN and UNOS Liver and Intestinal Organ Transplant Committee; or
- Candidates must satisfy diagnostic criteria for hilar cholangiocarcinoma: malignant-appearing stricture on cholangiography and one of the following: carbohydrate antigen 19-9 100 U/mL, or and biopsy or cytology results demonstrating malignancy, or aneuploidy. The tumor should be considered unresectable on the basis of technical considerations or underlying liver disease (eg, primary sclerosing cholangitis); or
- If cross-sectional imaging studies (computed tomography scan, ultrasound, magnetic resonance imaging) demonstrate a mass, the mass should be 3 cm or less; or
- Intra- and extrahepatic metastases should be excluded by cross-sectional imaging studies of the chest and abdomen at the time of initial exception and every 3 months before score increases; or
- Regional hepatic lymph node involvement and peritoneal metastases should be assessed by operative staging after completion of neoadjuvant therapy and before liver transplant; or Endoscopic ultrasound-guided aspiration of regional hepatic lymph nodes may be advisable to exclude individuals with obvious metastases before neoadjuvant therapy is initiated; or
- Transperitoneal aspiration or biopsy of the primary tumor (either by endoscopic ultrasound, operative, or percutaneous approaches) should be avoided because of the high risk of tumor seeding associated with these procedures.
Living Donor Criteria
Donor morbidity and mortality are prime concerns in donors undergoing right lobe, left lobe, or left lateral segment donor partial hepatectomy as part of living donor liver transplant. Partial hepatectomy is a technically demanding surgery, the success of which may be related to the availability of an experienced surgical team. The American Society of Transplant Surgeons proposed the following guidelines for living donors (American Society of Transplant Surgeons: Ethics Committee. American Society of Transplant Surgeons' position paper on adult-to-adult living donor liver transplant;
- They should be healthy individuals who are carefully evaluated and approved by a multidisciplinary team including hepatologists and surgeons to assure that they can tolerate the procedure; or
- They should undergo evaluation to ensure that they fully understand the procedure and associated risks; or
- They should be of legal age and have sufficient intellectual ability to understand the procedures and give informed consent; or
- They should be emotionally related to the recipients; or
- They must be excluded if the donor is felt or known to be coerced; or
- They need to have the ability and willingness to comply with long-term follow-up.